Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT05650476 Available - Clinical trials for Metastatic Castration-Resistant Prostate Cancer

Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)

Start date: n/a
Phase:
Study type: Expanded Access

Provide pre-approval single-patient Expanded Access (Compassionate Use) of talazoparib for patients with metastatic castration-resistant prostate cancer.

NCT ID: NCT05619367 Available - Clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)

A Compassionate Use (CU) Program of Odronextamab

Start date: n/a
Phase:
Study type: Expanded Access

Provide compassionate use of odronextamab

NCT ID: NCT05592743 Available - Neoplasms Clinical Trials

Vorasidenib Expanded Access Program

Start date: n/a
Phase:
Study type: Expanded Access

This is an expanded access program to provide vorasidenib for treatment of patients 12 years or older with IDH1- or IDH2-mutated glioma.

NCT ID: NCT05572996 Available - Clinical trials for Pulmonary Hypertension

Inhaled Treprostinil Expanded Access Program in Pulmonary Hypertension Associated With Interstitial Lung Disease

Start date: n/a
Phase:
Study type: Expanded Access

This is an Expanded Access Program (EAP) for eligible participants with Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) designed to provide access to Inhaled Treprostinil. Availability will depend on territory elegibility.

NCT ID: NCT05518838 Available - Clinical trials for Diffuse Intrinsic Pontine Glioma

Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered

Start date: n/a
Phase:
Study type: Expanded Access

To provide OKN-007 for compassionate use in patients with diffuse midline glioma, H3 K27-altered (DMG), including diffuse intrinsic pontine glioma (DIPG), pediatric and young adult patients with high-grade diffuse midline glioma will be treated under this Intermediate-sized expanded access treatment protocol.

NCT ID: NCT05494411 Available - Clinical trials for Urothelial Carcinoma

Named Patient Program for Mitomycin for Pyelocalyceal Solution

Start date: n/a
Phase:
Study type: Expanded Access

This program provides controlled, pre-approval access to JELMYTO in response to unsolicited requests by physicians, hospitals, pharmacies, distributors, ministries of health or other parties on behalf of specific, or named patients, in select countries where JELMYTO has not yet received a marketing authorization and in situations when patients have exhausted all available treatment options.

NCT ID: NCT05344508 Available - Clinical trials for Non-Cystic Fibrosis Bronchiectasis

An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis Bronchiectasis

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this study is to allow early access to brensocatib for participants with non-cystic fibrosis bronchiectasis (NCFBE) who have successfully completed the INS1007301 ASPEN Clinical trial.

NCT ID: NCT05222412 Available - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria (PNH)

Managed Access Programs for LNP023, Iptacopan

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this registration form is to list all Managed Access Programs (MAPs) related to LNP023, Iptacopan

NCT ID: NCT05219266 Available - Clinical trials for Acute Myeloid Leukemia

Managed Access Programs for PKC412, Midostaurin

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this registration is to list Managed Access Programs (MAPs) related to PKC4, Midostaurin.

NCT ID: NCT05172700 Available - Clinical trials for Waldenstrom Macroglobulinemia

Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer

Start date: n/a
Phase:
Study type: Expanded Access

This is an expanded access program for eligible participants with a previously treated B-cell cancer who are ineligible for an ongoing pirtobrutinib clinical trial. The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.